YU16403A - 4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja - Google Patents

4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja

Info

Publication number
YU16403A
YU16403A YU16403A YUP16403A YU16403A YU 16403 A YU16403 A YU 16403A YU 16403 A YU16403 A YU 16403A YU P16403 A YUP16403 A YU P16403A YU 16403 A YU16403 A YU 16403A
Authority
YU
Yugoslavia
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
halogenated
Prior art date
Application number
YU16403A
Other languages
English (en)
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Gunter Kaufmann
Hans-Udo Schweikert
Gerd Muller
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU16403A publication Critical patent/YU16403A/sh
Publication of RS50305B publication Critical patent/RS50305B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pronalazak se odnosi na 17-metilen steroide. Postupak za njihovu proizvodnju i farmaceutske sastave koji sadrže ova jedinjenja. Jedinjenja pronalaska imaju aktivni profil hibridnog karaktera takvog da se ponašaju kao inhibitori 5α-reduktaze i, u isto vreme, kao gestageni. Pomenuta jedinjenja su tako skrojena za lečenje medicinskih poremećaja koji su, kod muškaraca i žena, rezultat povećanog nivoa androgena u odredjenim organima i tkivima. Jedinjenja pronalaska kombinovana sa drugim hormonskim supstancama kao što su estrogen, testosteron ili potentni androgen su skrojena kao kontraceptivna sredstva za žene i muškarce.[The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5α-reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
YUP-164/03A 2000-09-04 2001-08-29 4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja RS50305B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (de) 2000-09-04 2000-09-04 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen

Publications (2)

Publication Number Publication Date
YU16403A true YU16403A (sh) 2006-05-25
RS50305B RS50305B (sr) 2009-09-08

Family

ID=7655148

Country Status (29)

Country Link
EP (1) EP1423407B1 (sh)
JP (1) JP2004513084A (sh)
KR (1) KR100530816B1 (sh)
CN (1) CN1262560C (sh)
AT (1) ATE319733T1 (sh)
AU (2) AU2002210470B2 (sh)
BG (1) BG107594A (sh)
BR (1) BR0113618A (sh)
CA (1) CA2421302C (sh)
DE (2) DE10043846A1 (sh)
DK (1) DK1423407T3 (sh)
EA (1) EA006387B1 (sh)
EE (1) EE05186B1 (sh)
ES (1) ES2260294T3 (sh)
HK (1) HK1060135A1 (sh)
HR (1) HRP20030256A2 (sh)
HU (1) HUP0300936A3 (sh)
IL (2) IL154666A0 (sh)
ME (1) MEP14408A (sh)
MX (1) MXPA03001912A (sh)
NO (1) NO325012B1 (sh)
NZ (1) NZ524485A (sh)
PL (1) PL360669A1 (sh)
PT (1) PT1423407E (sh)
RS (1) RS50305B (sh)
SK (1) SK286757B6 (sh)
UA (1) UA74592C2 (sh)
WO (1) WO2002019971A1 (sh)
ZA (1) ZA200301715B (sh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
AT12800U1 (de) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
WO2002000681A1 (en) * 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
WO2002019971A1 (de) 2002-03-14
SK2442003A3 (en) 2003-08-05
DE50109175D1 (de) 2006-05-04
SK286757B6 (sk) 2009-05-07
ZA200301715B (en) 2004-08-13
CN1452628A (zh) 2003-10-29
NO325012B1 (no) 2008-01-14
PL360669A1 (en) 2004-09-20
WO2002019971A9 (de) 2002-08-08
HUP0300936A2 (hu) 2003-11-28
MEP14408A (en) 2010-06-10
EE05186B1 (et) 2009-06-15
HUP0300936A3 (en) 2010-01-28
BR0113618A (pt) 2003-07-15
RS50305B (sr) 2009-09-08
MXPA03001912A (es) 2004-07-08
EA200300322A1 (ru) 2003-10-30
CA2421302A1 (en) 2003-03-03
PT1423407E (pt) 2006-07-31
DK1423407T3 (da) 2006-07-03
UA74592C2 (en) 2006-01-16
IL154666A (en) 2008-12-29
KR100530816B1 (ko) 2005-11-25
DE10043846A1 (de) 2002-04-04
EA006387B1 (ru) 2005-12-29
EE200300087A (et) 2005-02-15
HRP20030256A2 (en) 2005-10-31
CA2421302C (en) 2007-08-14
NO20030989L (no) 2003-05-02
EP1423407A1 (de) 2004-06-02
BG107594A (bg) 2003-09-30
AU2002210470B2 (en) 2006-07-20
IL154666A0 (en) 2003-09-17
KR20030028836A (ko) 2003-04-10
AU1047002A (en) 2002-03-22
NZ524485A (en) 2005-11-25
NO20030989D0 (no) 2003-03-03
ATE319733T1 (de) 2006-03-15
EP1423407B1 (de) 2006-03-08
JP2004513084A (ja) 2004-04-30
ES2260294T3 (es) 2006-11-01
HK1060135A1 (en) 2004-07-30
CN1262560C (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
IL149448A0 (en) New topical estrogen-progestogen compositions with a systemic effect
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
MEP38008A (en) Drospirenone for hormone replacement therapy
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
MXPA03001859A (es) Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
WO2002019982A3 (en) Cosmetic composition and method for reducing or preventing wrinkling
SG154323A1 (en) Estrogen replacement therapy
ZA971965B (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination for the production of a pharmaceutical agent for treating a relative and absolute androgen deficiency in men.
YU16403A (sh) 4-halogenovani 17-metilen steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja
MXPA05008347A (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
Whitehead Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data
JO2334B1 (en) Drospirenone for hormone replacement therapy